Introduction The treatment algorithm of advanced hepatocellular carcinoma (HCC) has
evolved since the introduction of immunotherapy. The IMbrave150 trial set atezolizumab …

High levels of vascular endothelial growth factor (VEGF) released from hypoxic tumor cells
and the vascular endothelium induce angiogenesis, thereby contributing to proliferation …

4074 Background: Advanced HCC is a lethal cancer with a high unmet medical need. Single-
agent immunotherapy with PD-L1/PD-1 blockade or treatment (Tx) with anti-angiogenic …

Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been
developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function …

Simple Summary Hepatocellular carcinoma is one of the most common cancers in the world
with increasing incidence. In advanced stages, according to the Barcelona Clinic Liver …

Background: Agents targeting angiogenesis or PD-L1/PD-1 signalling represent 2 types of
approved treatments (tx) for HCC. In addition to its anti-angiogenic activity, bevacizumab …

Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Background The combination of atezolizumab and bevacizumab showed encouraging
antitumor activity and safety in a phase 1b trial involving patients with unresectable …

Introduction The aim of this retrospective proof-of-concept study was to compare different
second-line treatments for patients with hepatocellular carcinoma and progressive disease …